SCHEMBL3242998

SCHEMBL3242998

O=C(CCC(=O)N1CCc2ccccc2C1c1ccccc1)NCCc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HHAT Q5VTY9 3/20 0.54
CYP2D6 P10635 1/20 0.53
HDAC8 Q9BY41 4/20 0.50
HDAC3 O15379 3/20 0.50
HDAC1 Q13547 3/20 0.50
HDAC2 Q92769 3/20 0.50
NCOR2 Q9Y618 3/20 0.50
POLB P06746 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ACE P12821 1/20 0.45
CHRM2 P08172 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
NPC1 O15118 1/20 0.44
MITF O75030 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
XBP1 P17861 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30795973 1.00 HHAT (0.54) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL3239044 0.94 L3MBTL1 (0.53) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL30795079 0.94 L3MBTL1 (0.53) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL30824751 0.89 HHAT (0.56) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL3240992 0.89 HHAT (0.56) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL3242891 0.88 HHAT (0.58) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL30794650 0.88 HHAT (0.58) HHATCYP2D6HDAC8HDAC3HDAC1
SCHEMBL3238899 0.88 LMNA (0.47) HHATCYP2D6POLBL3MBTL1NPC1
SCHEMBL30795877 0.88 LMNA (0.47) HHATCYP2D6POLBL3MBTL1NPC1
SCHEMBL17117236 0.85 HHAT (0.54) HHATCYP2D6HDAC8HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367700-B2 Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-02-05 US claimed
US-20100152234-A1 Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2010-06-17 US claimed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed
US-8367700-B2 Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators GRUENENTHAL GMBH (DE) 2013-02-05 US disclosed
US-20100152234-A1 Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators GRUNENTHAL GMBH (DE) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152234-A1 Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators KCNAB1, KCNQ2, KCNQ1 HHAT 2690/4885CYP2D6 611/4885HDAC8 1358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.